ADVERTISEMENT

Enforcement

California Firm Too Busy To Defend Ad Claims For NAD+ Supplement It Previously Marketed

Virgin Scent didn’t respond to NAD attorneys’ “repeated outreach attempts” asking for evidence supporting ad claims for Artnaturals NAD+ challenged by another NAD+ supplement marketer, Reus Research.

Latest OTC Eye Drop Production Problem In US Prompts Firm To Close Doors After Recalls

BRS Analytical Services in St. Louis recalled more than 75,000 cases of redness and lubricating eye drops and committed “to permanently cease production of all drugs.”

US FDA Plans Move Inspectorate Back To More Generalist Organization

The “Simple Reform” initiative would reverse a 2017 move to ensure FDA investigators were experts in the commodity they inspected or in clinical research regulations.

Hong Kong OTC Antifungal Pen Firm Erases Challenged US Ad Claims Without Argument

National Advertising Division says XF Agencija permanently discontinued benefits and efficacy ad claims for Lunavia undecylenic acid 25% nail pen challenged by Advantice Health, marketer of Kerasal fungal nail renewal brand.

One Plus, More Minuses In Review Of NAD+ Supplement Firm’s Advertising Claims

National Advertising Division, on challenge by NAD+ trailblazer Niagen Bioscience, found substantiation lacking for Cata-Kor NAD+ and NAD+ Core product content and health benefit claims and no clear and conspicuous disclosures for brand’s influencer posts.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

NPA On Clock To Continue Challenge To FDA ‘Drug Preclusion’ Policy For Dietary Ingredients

FDA rejects NPAs arguments for clarity on when it recognizes start of investigational new drug programs and what constitutes “substantial clinical investigations” for an IND. Clock starts after FDA met twice-extended deadline to provide answers to NPA’s questions in a 2023 petition.

US FDA Facility Inspections, Website Reviews Paused With FY 2026 Budget On Hold

Continuing work includes “for cause and certain surveillance inspections of regulated facilities” and “criminal enforcement work and certain civil investigations” as White House mulls layoffs rather than furloughs during federal government shutdown.

Trump Post Offers Stamp Of Approval For Lawful Use Of Hemp In Health And Wellness Products

President posts pro-hemp video on Truth platform as FDA maintains policy that cannabis and hemp are unlawful for use in supplements and food because both types of botanicals have been approved for use as drug ingredients in the US.

Proponents Say Scheduling 7-OH ‘Would Be A Disaster’ As FDA Says All Kratom Unlawful For Use

Holistic Alternative Recovery Trust advocacy group for 7-OH use to help people stop using opioids offers arguments from a variety of public health and consumer advocacy groups that scheduling 7-OH “would be a disaster.”

US FDA Notes Honey Drops Eye Care, Nasal Spray Brain Boost In Recent Warning Letters

Recent FDA warning letters hit typical problems in consumer health space such as manufacturing quality control deficiencies, but also note honey offered for eye infections and nasal spray to enhance cognitive function.

Advertising Claim Review For Coffee With Benefits: Eye-Opener For Firms In Percolating Market?

Ryze Superfoods withdraws claims National Advertising Division asks to review from its ongoing monitoring of consumer products advertising, including that coffee enhances mental acuity and provides other health benefits.